Tg Therapeutics Inc Stock Price, News & Analysis

TG Therapeutics (NASDAQ: TGTX) said it ranked #27 on the 2025 Deloitte Technology Fast 500, a list of North America’s 500 fastest-growing tech and life sciences companies.

The company attributed its growth from fiscal years 2021–2024 to BRIUMVI revenues after BRIUMVI received FDA approval in December 2022 to treat adults with relapsing forms of multiple sclerosis. Management credited employee execution, continued product adoption, and patient/provider trust for the result.

TG Therapeutics (NASDAQ: TGTX) announced that Chairman and CEO Michael S. Weiss will participate in the TD Cowen Immunology & Inflammation Summit, a virtual event running November 12–13, 2025. The company said the fireside chat is scheduled for Wednesday, November 12, 2025 at 10:00 AM ET. A live webcast will be available on the company’s Investors & Media Events page at http://ir.tgtherapeutics.com/events. The presentation offers investors an opportunity to hear management commentary and participate via the live webcast.

TG Therapeutics (NASDAQ: TGTX) reported third-quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million (Q3 U.S. BRIUMVI +84% YoY, +10% QoQ). The company raised full‑year 2025 guidance to ≈$600 million global revenue and ≈$585 million U.S. BRIUMVI net revenue. Management completed a $100 million share repurchase and authorized an additional $100 million program.

R&D expense was $40.9 million in Q3 and SG&A was $63.4 million. Net income benefited from a non‑recurring tax benefit of ≈$365.0 million. Cash, cash equivalents and investment securities totaled $178.3 million as of September 30, 2025. Conference call scheduled November 3, 2025 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) will hold a conference call on Monday, November 3, 2025 at 8:30 AM ET to discuss third quarter 2025 financial results and provide a business outlook for the remainder of 2025.

Michael S. Weiss, Chairman and CEO, will host. The company will issue a press release with financial results prior to the call. Investors can join by phone (1-877-407-8029 U.S.; 1-201-689-8029 outside the U.S.) or listen via a live webcast on the Investors & Media Events page at www.tgtherapeutics.com. An audio replay will be available on the company website for 30 days after the call.

TG Therapeutics (NASDAQ: TGTX) announced completion of enrollment in the randomized cohort of the Phase 3 ENHANCE trial testing a consolidated Day 1/Day 15 IV dosing schedule for BRIUMVI (ublituximab) in relapsing multiple sclerosis (RMS) on Oct 28, 2025.

The trial's primary endpoint is noninferior exposure measured by AUC at Week 16. ENHANCE is randomized, double-blind and placebo-controlled and will assess pharmacokinetics, safety (including infusion-related reactions), and efficacy via T1 Gd-enhancing lesions. Dosing arms compare a single 600 mg Day 1 dose plus Day 15 placebo versus 150 mg Day 1 then 450 mg Day 15, with a 450 mg dose at Week 24.

Company commentary notes potential for a simplified regimen to improve patient convenience and infusion center efficiency and states that, if data are positive, the regimen could be ready for launch in 2027.

TG Therapeutics (NASDAQ: TGTX) announced impressive 6-year data for BRIUMVI® (ublituximab-xiiy) in treating relapsing multiple sclerosis (RMS). The data revealed that 89.9% of patients remained free from disability progression after 6 years of continuous treatment.

Key highlights include an exceptionally low annualized relapse rate of 0.012 in year 6 (equivalent to one relapse per 83 years of treatment), and 17% of continuous BRIUMVI patients achieved Confirmed Disability Improvement. The ENHANCE study demonstrated that a modified single-dose regimen was well-tolerated, while the ENABLE real-world study showed an on-treatment relapse rate of 0.015, with 99.5% of participants reporting no relapses.

TG Therapeutics (NASDAQ: TGTX) has announced three upcoming presentations featuring BRIUMVI® (ublituximab-xiiy) data for multiple sclerosis at the 2025 ECTRIMS annual meeting in Barcelona, Spain from September 24-26, 2025.

The presentations include: 1) An oral presentation on long-term efficacy and safety data from six years of the ULTIMATE I and II trials' open-label extension, 2) An ePoster on safety and tolerability from the ENHANCE study with modified dosing regimen, and 3) An ePoster presenting real-world clinical experience from the ENABLE Phase 4 observational study.

All presentations will be available on the company's website after the conference.

TG Therapeutics (NASDAQ: TGTX) has initiated enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI for relapsing multiple sclerosis (RMS). The trial aims to develop a self-administered version of BRIUMVI, which is currently approved as an intravenous (IV) infusion.

The study will compare two subcutaneous dosing regimens (every 8 weeks and every 12 weeks) against the current IV format. If successful, BRIUMVI would become the only anti-CD20 therapy offering both IV and subcutaneous options, potentially accessing an additional 40% of the RMS CD20 market that prefers self-injectable treatments. The company anticipates potential approval by 2028.

TG Therapeutics (NASDAQ:TGTX) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, NY. The company's Chairman and CEO, Michael S. Weiss, will engage in a fireside chat on Monday, September 8, 2025, at 10:30am ET.

Investors can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website at http://ir.tgtherapeutics.com/events.